AI Article Synopsis
- Pancreatic ductal adenocarcinoma (PDAC) is difficult to treat with radiation, but researchers developed a new treatment combining gold nanoparticles (AuNPs) and a peptide that targets a specific protein (plectin-1) found on PDAC cells.
- The new AuNP-PTP complex showed improved targeting and increased cancer cell death in lab tests when combined with low-energy X-ray irradiation, compared to using unmodified AuNPs alone.
- Important safety tests indicated that this treatment did not cause harmful effects in mice for up to six weeks, suggesting that AuNP-PTP could be an effective addition to radiotherapy for PDAC.
Article Abstract
Pancreatic ductal adenocarcinoma (PDAC) is radioresistant. Due to their strong X-ray absorption capacity, gold nanoparticles (AuNPs) have been used as radiosensitizers for cancer therapeutics. Herein, we describe a novel conjugate complex consisting of a peptide for targeting plectin-1 (PTP) specifically expressed on the PDAC cell membrane and AuNPs, termed AuNP-PTP, to be used for PDAC radiotherapy and . Previous studies revealed that compared with unmodified AuNPs, AuNP-PTP along with relevant low-energy X-ray irradiation of 6 MV at a dose of 2 Gy (RF) increased the targeting efficiency and induced apoptosis in treated PANC-1 cells and tumours. Importantly, extensive histopathological examination did not reveal evidence of acute or chronic injury in mice due to AuNPs or AuNP-PTP for up to six weeks despite the presence of X-ray exposure. The delicate AuNP-PTP hybrid provides a novel strategy to enhance radiotherapy efficiency in PDAC treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1166/jbn.2020.2898 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Pancreatic ductal adenocarcinoma (PDAC) is difficult to treat with radiation, but researchers developed a new treatment combining gold nanoparticles (AuNPs) and a peptide that targets a specific protein (plectin-1) found on PDAC cells.
- The new AuNP-PTP complex showed improved targeting and increased cancer cell death in lab tests when combined with low-energy X-ray irradiation, compared to using unmodified AuNPs alone.
- Important safety tests indicated that this treatment did not cause harmful effects in mice for up to six weeks, suggesting that AuNP-PTP could be an effective addition to radiotherapy for PDAC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!